These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 6135575)

  • 1. A comparison of the effects of reversible and irreversible inhibitors of aromatic L-amino acid decarboxylase on the half-life and other pharmacokinetic parameters of oral L-3,4-dihydroxyphenylalanine.
    Huebert ND; Palfreyman MG; Haegele KD
    Drug Metab Dispos; 1983; 11(3):195-200. PubMed ID: 6135575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Irreversible inhibition of aromatic-L-amino acid decarboxylase by alpha-difluoromethyl-DOPA and metabolism of the inhibitor.
    Ribéreau-Gayon G; Palfreyman MG; Zraïka M; Wagner J; Jung MJ
    Biochem Pharmacol; 1980 Sep; 29(18):2465-9. PubMed ID: 7426053
    [No Abstract]   [Full Text] [Related]  

  • 3. Peripheral pharmacokinetic handling and metabolism of L-dopa in the rat: the effect of route of administration and carbidopa pretreatment.
    Rose S; Jenner P; Marsden CD
    J Pharm Pharmacol; 1991 May; 43(5):325-30. PubMed ID: 1680174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective effects of L-dopa and carbidopa combined treatments on human catecholaminergic cells.
    Colamartino M; Padua L; Meneghini C; Leone S; Cornetta T; Testa A; Cozzi R
    DNA Cell Biol; 2012 Nov; 31(11):1572-9. PubMed ID: 23020119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. alpha-difluoromethyl DOPA, a new enzyme-activated irreversible inhibitor of aromatic L-amino acid decarboxylase.
    Palfreyman MG; Danzin C; Bey P; Jung MJ; Ribereau-Gayon G; Aubry M; Vevert JP; Sjoerdsma A
    J Neurochem; 1978 Oct; 31(4):927-32. PubMed ID: 308998
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of L-DOPA/carbidopa administration on the levels of L-DOPA, other amino acids and related compounds in the plasma, brain and heart of the rat.
    Diederich C; Milakofsky L; Hare TA; Hofford JM; Dadmarz M; Vogel WH
    Pharmacology; 1997 Sep; 55(3):109-16. PubMed ID: 9346399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the effects of decarboxylase inhibitors on L-dopa-induced circling behavior and the conversion of dopa to dopamine in the brain.
    Goodale DB; Moore KE
    Life Sci; 1976 Sep; 19(5):701-6. PubMed ID: 957902
    [No Abstract]   [Full Text] [Related]  

  • 8. The effect of carbidopa on plasma and muscle levels of L-dopa, dopamine, and their metabolites following L-dopa administration to rats.
    Rose S; Jenner P; Marsden CD
    Mov Disord; 1988; 3(2):117-25. PubMed ID: 3221899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of radiolabeled monofluoromethyl-Dopa to define the subunit structure of human L-Dopa decarboxylase.
    Maneckjee R; Baylin SB
    Biochemistry; 1983 Dec; 22(26):6058-63. PubMed ID: 6661425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depression of sympathetic nervous function by DL-alpha-monofluoromethyldopa, an enzyme-activated, irreversible inhibitor of L-aromatic amino acid decarboxylase.
    Fozard JR; Spedding M; Palfreyman MG; Wagner J; Möhring J; Koch-Weser J
    J Cardiovasc Pharmacol; 1980; 2(3):229-45. PubMed ID: 6156322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset.
    Tayarani-Binazir KA; Jackson MJ; Fisher R; Zoubiane G; Rose S; Jenner P
    Eur J Pharmacol; 2010 Jun; 635(1-3):109-16. PubMed ID: 20303948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of carbidopa and entacapone pretreatment on the L-dopa pharmacokinetics and metabolism in blood plasma and skeletal muscle in beagle dog: an in vivo microdialysis study.
    Deleu D; Sarre S; Ebinger G; Michotte Y
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1323-31. PubMed ID: 7791104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of D,L-alpha-monofluoromethyldopa to distinguish subcellular pools of aromatic amino acid decarboxylase in mouse brain.
    Gardner CR; Richards MH
    Brain Res; 1981 Jul; 216(2):291-8. PubMed ID: 6166354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. L-dopa facilitates the release of endogenous norepinephrine and dopamine via presynaptic beta 1- and beta 2-adrenoceptors under essentially complete inhibition of L-aromatic amino acid decarboxylase in rat hypothalamic slices.
    Goshima Y; Nakamura S; Misu Y
    Jpn J Pharmacol; 1990 May; 53(1):47-56. PubMed ID: 1972204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of 3,4-dihydroxyphenylpyruvic acid and its triacetylated derivative on DOPA decarboxylase.
    Lindén IB; Neuvonen PJ; Vapaatalo H
    Acta Pharmacol Toxicol (Copenh); 1982 Sep; 51(3):266-9. PubMed ID: 7136732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benserazide decreases central AADC activity, extracellular dopamine levels and levodopa decarboxylation in striatum of the rat.
    Jonkers N; Sarre S; Ebinger G; Michotte Y
    J Neural Transm (Vienna); 2001; 108(5):559-70. PubMed ID: 11459076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homologs of dopa, alpha-methyldopa, and dopamine as potential cardiovascular drugs.
    Winn M; Rasmussen R; Minard F; Kyncl J; Plotnikoff N
    J Med Chem; 1975 Apr; 18(4):434-7. PubMed ID: 1079053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of carbidopa administration on 6-[18F]fluoro-L-dopa kinetics in positron emission tomography.
    Hoffman JM; Melega WP; Hawk TC; Grafton SC; Luxen A; Mahoney DK; Barrio JR; Huang SC; Mazziotta JC; Phelps ME
    J Nucl Med; 1992 Aug; 33(8):1472-7. PubMed ID: 1634937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine metabolism following irreversible inactivation of aromatic amino acid decarboxylase in retina.
    Parkinson D; Baughman R; Masland RH; Rando RR
    J Neurosci; 1981 Nov; 1(11):1205-10. PubMed ID: 6796656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inactivation of 3-(3,4-dihydroxyphenyl)alanine decarboxylase by 2-(fluoromethyl)-3-(3,4-dihydroxyphenyl)alanine.
    Maycock AL; Aster SD; Patchett AA
    Biochemistry; 1980 Feb; 19(4):709-18. PubMed ID: 7356954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.